

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	: Han et al.)	Examiner:
)	Sahar Javanmard
Serial No.	: 10/575,683)	
)	Art Unit:
Cnfrm. No.	: 4626)	1627
)	
Filed	: October 14, 2004)	
)	
For	: TREATING AN INFLAMMATORY DISORDER)	
	OR INHIBITING RESPIRATORY BURST IN)	
	ADHERENT NEUTROPHILS WITH CHEMICAL)	
	INHIBITORS OF NEUTROPHIL ACTIVATION)	

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby request a corrected filing receipt for the above-identified application. On the enclosed marked-up copy of the official filing receipt (attached hereto as **Exhibit A**), the residence address of inventor Carl F. Nathan is incorrect. The information for Carl F. Nathan currently reads, "Carl F. Nathan, New York, NY," but should read, "Carl F. Nathan, Larchmont, NY" (correction underlined). In support of this change, the previously-filed combined declaration/power of attorney (attached hereto as **Exhibit B**) indicates the correct residence address of inventor Carl F. Nathan. In addition, the Supplemental Application Data Sheet filed herewith corrects both the mailing address and city of residence of inventor Carl F. Nathan.

Applicants also bring to the attention of the U.S. Patent and Trademark Office that on page 2 of the previously-filed combined declaration, under "**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS**," the PCT International Applicant Number is incorrectly noted as "PCT/US2004/030161," filed on "15 September 2004." However, the PCT International Application Number (of which the present application is a national stage filing under

35 U.S.C. § 371) is correctly recited on page 1 of the combined declaration as “PCT/US2004/03391,” which was filed “on 14 October 2004.” This information also appears correct on both the official filing receipt, the originally-filed Application Data Sheet, and the Supplemental Application Data Sheet submitted herewith.

Applicants note that under 37 CFR §1.76 (d)(1), discrepancies between the combined declaration and application data sheet will be controlled by the last submitted information (*i.e.*, the presently-filed Supplemental Application Data Sheet). Thus, the presently-filed Supplemental Application Data Sheet acts to correct this error in the PCT International Application Number listed on page 2 of the previously-filed combined declaration.

Applicants believe that no fee is due. However, the Commissioner is hereby authorized to charge any necessary fees to Deposit Account No. 14-1138.

Respectfully submitted,

Date: October 25, 2010

/Michael L. Goldman/
Michael L. Goldman
Registration No. 30,727

NIXON PEABODY LLP
1100 Clinton Square
Rochester NY 14604-1792
Telephone: (585) 263-1304
Facsimile: (585) 263-1600

Exhibit A



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/575,683	08/31/2006	1617	1065	196034542	23	48	2

CONFIRMATION NO. 4626

26774
NIXON PEABODY LLP - PATENT GROUP
CLINTON SQUARE
P.O. BOX 31051
ROCHESTER, NY 14603-1051

FILING RECEIPT



OC000000020869748

Date Mailed: 10/18/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Hyunsil Han, New York, NY;
Gang Lin, New York, NY;
Carl F. Nathan, New York, NY;

Larchmont

Power of Attorney: The patent practitioners associated with Customer Number **26774**.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/33914 10/14/2004
which claims benefit of 60/510,843 10/14/2003

Foreign Applications

If Required, Foreign Filing License Granted: 10/17/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/575,683**

Projected Publication Date: 01/25/2007

ENTERED
Nixon Peabody LLP

Non-Publication Request: No

Early Publication Request: No

OCT 25 2006
FILE 19603/4542
DKT JB

** SMALL ENTITY **

Title

Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

Exhibit B

COMBINED DECLARATION FOR PATENT
APPLICATION AND POWER OF ATTORNEY
(Includes Reference to PCT International Applications)

ATTORNEY'S DOCKET
NUMBER

19603/4542 (CRF D-3303-03)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**TREATING AN INFLAMMATORY DISORDER OR INHIBITING RESPIRATORY BURST IN ADHERENT
NEUTROPHILS WITH CHEMICAL INHIBITORS OF NEUTROPHIL ACTIVATION**

the specification of which (check only one item below):

☐ is attached hereto.

☐ was filed as U.S. Patent Application Serial No. _____ on _____ and was amended on _____
(if applicable).

☒ was filed as PCT International Application Number PCT/US2004/033914 on 14 October 2004 and assigned U.S.
Serial No. 10/575,683.




I hereby state that I have reviewed and understand the contents of the above-identified specifications, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim priority benefits under Title 35, United States Code, § 119 of any application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States listed below and have also identified below any application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY (IF PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
USA	60/510,843	14 October 2003	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (Continued) (Includes Reference to PCT International Applications)				ATTORNEY'S DOCKET NUMBER 19603/4542 (CRF D-3303-03)	
I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT International filing date of this application:					
PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:					
U.S. APPLICATIONS			STATUS (Check One)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
PCT APPLICATIONS DESIGNATING THE U.S.					
PCT APPLICATION NO.	PCT FILING DATE	U.S. SERIAL NUMBERS ASSIGNED (if any)			
PCT/US2004/030161	15 September 2004			X	
POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) associated with the following customer number to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. 26774					
Send Correspondence to: 26774				Direct telephone calls to: Michael L. Goldman (585) 263-1304	
2 0 1	FULL NAME OF INVENTOR	FAMILY NAME HAN	FIRST GIVEN NAME Hyunsil	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY New York	STATE/FOREIGN COUNTRY New York	COUNTRY OF CITIZENSHIP Korea	
	POST OFFICE ADDRESS	P.O. ADDRESS 420 E. 70 th Street, Apt. 10C	CITY New York	STATE & ZIP CODE/COUNTRY New York 10021 U.S.A.	
2 0 2	FULL NAME OF INVENTOR	FAMILY NAME LIN	FIRST GIVEN NAME Gang	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY New York	STATE/FOREIGN COUNTRY New York	COUNTRY OF CITIZENSHIP China	
	POST OFFICE ADDRESS	P.O. ADDRESS 444 East 77 th Street, Apt. 3A	CITY New York	STATE & ZIP CODE/COUNTRY New York 10021 U.S.A.	
2 0 3	FULL NAME OF INVENTOR	FAMILY NAME NATHAN	FIRST GIVEN NAME Carl	SECOND GIVEN NAME F.	
	RESIDENCE & CITIZENSHIP	CITY New York	STATE/FOREIGN COUNTRY New York	COUNTRY OF CITIZENSHIP United States	
	POST OFFICE ADDRESS	P.O. ADDRESS 5 Edgewood Avenue	CITY Larchmont	STATE & ZIP CODE/COUNTRY New York 10538 U.S.A.	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.					
SIGNATURE OF INVENTOR 201		SIGNATURE OF INVENTOR 202		SIGNATURE OF INVENTOR 203	
					
DATE 6.26.2006		DATE 6.28.2006		DATE 6.28.06	